TLR 4 and 9 receptors agonists for preventing septic complications of post-traumatic immunodepression in patients hospitalized for severe traumatic injuries
US8636979B2 · kind B2 · utility
1Cited by
0References
11Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Dec 17, 2010 |
| Grant date | Jan 28, 2014 |
| Priority date | — |
| Expiry date | Dec 17, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns a pharmaceutical composition comprising at least one agonist of at least one Toll Like receptor (TLR) chosen from TLR 4 and 9, for use in the prophylactic treatment of septic complications of post-traumatic systemic immunodepression in a patient who has suffered one or more severe traumatic injuries and is hospitalized in particular in an intensive care unit. Preferably, said TLR 4 agonist is monophosphoryl lipid A (MPLA) or deacylated 3-O-monophosphoryl lipid A (3D-MPLA) and said TLR 9 agonist is a CpG oligodeoxynucleotide (CpG ODN).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.